Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk-adapted Plerixafor for Stem Cell Mobilization in Autologous HSCT
NCT07188090Phase 2
Key facts
- Status
- Recruiting
- Start
- Oct 2025
- Primary completion
- Dec 2027
- Countries
- 1
- Sponsor
- Thomas Jefferson University
- Modality
- Small Molecules
- Drugs
- plerixafor
- Conditions
- multiple myeloma (MM)Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)
01
Overview
Phase 2, open-label, single-arm trial of plerixafor in multiple myeloma (MM), Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), sponsored by Thomas Jefferson University. Primary endpoint: Incidence of Engraftment Syndrome. Started Oct 2025; status: recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Risk-adapted Mobilization
G-CSF with conditional Plerixafor based on mobilization yield.
03
Who it enrols
Adult patients with Multiple Myeloma, Hodgkin Lymphoma, or Non-Hodgkin Lymphoma undergoing autologous stem cell transplant with adequate organ function.
04
Endpoints
Primary
Incidence of Engraftment Syndrome
Secondary
Efficacy of Stem Cell Mobilization
Time to Neutrophil Engraftment
Time to Platelet Engraftment
Number of Collection Days
Length of Hospital Stay
Disease Response
Cell Composition
Cytokine Analysis
Beyond the preview
Go deeper on NCT07188090.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07188090.